320 W 10th Ave
Columbus, OH 43210
Phone: (614) 293-2268
Associate Professor, Hematology
I was recruited to the Division of Hematology-Oncology at the Ohio State University as an Assistant Professor, on the tenure track, in July 1999 and I was promoted to Associate Professor of Medicine with tenure in 2006.
After earning my MD degree at the University of Torino, Italy, I was introduced to bench research in the Laboratory of Dr. Luigi Pegoraro, where I worked on the role of hematopoietic growth factors in leukemia, later obtaining my Italian board certification in Oncology. I then pursued three years of additional research training as a post-doctoral fellow in the laboratory of Dr. Renato Baserga in Philadelphia, first at Temple University and then at Thomas Jefferson University (1990-1992). From 1992 to 1993 I was a research associate at Thomas Jefferson University. In the Laboratory of Dr. Baserga I studied basic mechanisms of human cell transformation by the SV40 virus and by insulin-like growth factor 1 (IGF-1) and its receptor (IGF-1R).
I completed a residency in Internal Medicine in 1996 and a Fellowship in Hematology/Oncology in 1999, at Indiana University (IU), Indianapolis, IN. During my residency and fellowship I wrote and published articles on various clinical hematology topics, including an original article (1997) and a review (2000) on the treatment of hyperleukocytosis in acute leukemia, both of which were widely quoted and led to invited lectures and additional manuscripts (2002 and 2007). I spent my first year of fellowship working in the Laboratory of Dr. Hal E. Broxmeyer, studying the mechanism of immunological anergy in T-cells from umbilical cord blood (UCB), work that remains relevant for the understanding of the decreased frequency of acute GVHD with UCB transplantation. During my last two years of fellowship I was awarded a SmithKline Beecham Research Fellowship Award and in my senior year I was selected to be Chief Fellow.
My initial career development at OSU was supported by a NCI/K23 grant (M.A. Caligiuri, Mentor). My work was focused on the clinical translation on in vitro and preclinical data from the Caligiuri Lab on the use of cytokine-antibody combinations in the treatment of lymphoma, leading to the completion of a Phase I study of IL-2 and rituximab in B-cell lymphoma, followed by a multi-institutional phase II trial. During this time, I also started my work on EBV-associated lymphomas, which led to the publication of a paper in Blood demonstrating that patients with post-transplant lymphomas (PTLD) treated with standardized reduction of immunosuppressive drugs and antiviral therapy mount robust immune responses to EBV lytic antigens, achieve a high rate of complete responses, and that monitoring of absolute CD8+ T-cell counts in the peripheral blood is a useful marker to predict response. This work changed the standard of care for PTLD at OSU and received national attention. Since 2000 I have been a member of the NCCN NHL committee. In 2004 I was a faculty inductee of the AOA.
Since 2006 my work has focused on studying new treatments and biomarkers in T/NK-cell and EBV lymphoma. I have established one of the few multimodality cutaneous lymphoma clinics in the U.S, and have made the OSUCCC an internationally-recognized center for the study and treatment of cutaneous lymphoma. This research has been, and is currently funded by the NCI (P30 CA016058; R21 CA164911; R21 CA181997) and by an OSU Pelotonia Idea Award. I was an invited grant reviewer for the Netherlands Organisation for Scientific Research (NWO) and the National Medical Research Council, Singapore. I was on the editorial board of Leukemia (2002-2005) and I am Guest Associated Editor of Frontiers in Hematology Oncology. I have brought to the Division and the CCC more than $1 million in clinical research funds (clinical trials), more than $2 million in laboratory research funds, and established a robust and reliable philanthropic program in my area of work.
Over the past 5 years I have assumed an international leadership role in the area of cutaneous lymphoma. I was Secretary-Treasurer of the United States Cutaneous Lymphoma Consortium (USCLC) from 2009 to 2013 and I am now President (2014-2016). As an Officer of the USCLC, I personally led the development and launching of the USCLC website and worked to promote cutaneous lymphoma at annual Hematology-Oncology meetings. Since 2011 I have been on the Board of Directors of the International Society of Cutaneous Lymphomas (ISCL). In 2009 I was the co-Chair of the Cutaneous Lymphoma Summit, in New York City, the first integrated multidisciplinary meeting in cutaneous lymphoma in the U.S. I am a member of the International Program Committee of the World Congress of Cutaneous Lymphoma (last held in Berlin, 2013) and I am on the Program Committee of the 2014 World Cutaneous Malignancy Congress. I am a member of the Steering Committee of an international cutaneous lymphoma registry study, called CLIC (Cutaneous Lymphoma International Consortium). From 2011 to 2013 I was on the BOD of the Cutaneous Lymphoma Foundation (CLF), where I remain co-Chair of the Medical Affairs Committee. In this capacity, I designed and helped launching The CLARIONS Research Award Program, the 2013 signature initiative of the CLF. I also edited and directed the production of the CLF Patient Education Guide, with a distribution of ~50,000 copies in North America.
I have an extensive and successful record of fundraising for the OSUCCC. In 2009 I created Team CTCL, a cycling group that rides annually in Pelotonia, the Columbus biking event that has raised more than $61 million for the OSUCCC. Team CTCL has fundraised ~$170,000 for Pelotonia. In addition, I have partnered with the non-profit Cesidia Fund for Lymphoma Research (Columbus, OH), which hosts an annual fundraising dinner for T-cell and Cutaneous Lymphoma that has brought nearly $200,000 in research funds for T/NK-cell lymphoma. Since 2012, I have been a member of the ASH Foundation and Development Committee.
I have worked extensively in the field of lymphoma education and mentoring, both at the academic level and in the community. I have taught undergraduate and graduate classes at OSU and was selected as the Cancer Signature Program liaison of the OSUCCC for the OSU Research Education Council Committee. For the past 3 years I have coordinated a post-graduate course on translational cancer research. I have mentored students and fellows in their application for research awards and funding. I am also very active in patient education forums, on behalf of patient advocacy organizations, such as the Cutaneous Lymphoma Foundation, CancerCare, and the Leukemia Lymphoma Society.
Dermatology, Dermatopathology, Hematology, Immunopathology, Medical Oncology
I have been serving as advisor to the nursing staff of the MCLC, specifically Ms. Deborath Wiseman, RN, and Ms. Maria Tucker, RN. The focus of my advising has been the creation of a support group for our cutaneous lymphoma patients. I have assisted Ms. Wiseman and Ms. Tucker in the development of the educational program for the support group, and I serve as a speaker for the quarterly meetings.
In 2009 I was invited by Dr. Bruce Biagi, Director of the OSU Biomedical Science Program, to develop a new spring quarter course in cancer research for the BMS Program (“Cancer Research: bench to bedside and back”; BMS-583) and assume the role of Instructor, including evaluating and grading students at the end of the course. I developed a new curriculum for the class and recruited a set of lecturers. Over 3 years (2009-2011) I personally taught part of the curriculum, provided oversight and moderated all the class activities, and created a test for the final exam. The course was well received, and I had the opportunity to follow and interact with several of the BMS-583 students in their subsequent education, as MD/PhD students, or graduate students.
For the past 4 years (2009-2013) I have been the Instructor and coordinating faculty for IBGP 8800.02, a 10-week course on Translational Cancer Research which is part of the Master in Medical Science Program (MMSP, Dr. Bumgardner, Director). Students are a mixture of fellows, PhD, and MD,PhD. For this course, I developed an entirely new curriculum, which includes novel and original topics such as “Developing and running a multimodality research program”, “Working with patient advocacy organizations”, and “How to establish a database and a tissue bio-repository.” I selected all the lecturers for this class and I personally teach 2-3 lectures every year. I provide oversight and guide the in-class discussion for the entire course. Parts of this curriculum were integrated in the grant proposal for the NCI clinical T32 program, successfully submitted by the Divisions of Hematology and Medical Oncology (Devine and Villalona, PI).
|2012 - present||Brad Haverkos The Ohio State University. Graduated 2009. (NCI T32 candidate)|
|2012 - present||Kelly Tyler Ohio State University College of Medicine.|
|2000 - 2003||The Ohio State University.|
|2003||Shannon Puhalla The Ohio State University.|
|2004||Jeanna Knoble, The Ohio State University.|
|2004||Robert Winrow, The Ohio State University.|
|2004||The Ohio State University.|
|2005||Alexandra Jordan, The Ohio State University.|
|2005||Amanda Holbrook, The Ohio State University.|
|2005 - 2007||Terrence Grady, The Ohio State University. Graduated 2007. Mentored on: NCI T-32 Training Grant submission & Amgen Research Fellowship|
|2007||Katherine Martin, The Ohio State University.|
|2006 - 2008||Lapo Alinari, The Ohio State University. Visiting Physician Scientist from University of Bologna, Italy|
|2007 - 2009||Jay Erter, The Ohio State University. Graduated 2009.|
|2010 - 2011||Sean Carlson, The Ohio State University.|
|2011 - 2012||Francisca Kartono, The Ohio State University. Graduated 2012.|
|2010 - 2013||The Ohio State University.|
Porcu P and Tawa M, Editors. Guitart J, Hodak E.,Horwitz S, Hwang S, Lessin S, Lowenthal L, McCann S, Pinter Brown L, Young M, Zic J. A Patient's Guide to Understanding Cutaneous Lymphoma. Birmingham, MI, US|USA: Cutaneous Lymphoma Foundation, January 2012.
|2010 - present||State of Ohio Medical Board. License #35-76403 (active): State Medical Board of Ohio|
|2011 - present||Board Certified in Medical Oncology: American Board of Internal Medicine|
|1991 - 2001||Board Certified in General Oncology: University of Torino|
|1996 - 2006||Board Certified in Internal Medicine: American Board of Internal Medicine|
|1999 - 2009||Board Certified in Hematology: American Board of Internal Medicine|
Gaddy J, Porcu P, Broxmeyer HE. "Clinical and basic science studies of human umbilical cord blood (UCB). Implications for the graft versus leukemia (GVL) effect following cord blood transplantation." In Allogeneic Immunotherapy for Malignant Diseases 1st Edition. Edited by Barrett AJ and Jiang YZ. -. NY: Marcel Dekker, March 2000.
Porcu P., Blum K. "Hodgkin’s Disease: clinical features and making the diagnosis." In Sekeres MA, Kalaycio ME., and Bolwell BJ. Eds. “Clinical Malignant Hematology: A Textbook”. -. New York, NY, US|USA: McGraw-Hill, January 2007.
Porcu P. Bechtel, MA. "Therapy of primary cutaneous lymphomas." In The Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin. Edited by Magro C.M., Crawson N.A., Mihrn M.C.. -. New York City, NY, US|USA: Wiley and Son, January 2007.
Gross TG., Porcu P., Baiocchi RA. ". Non-Hodgkin’s lymphoma in immunodeficient hosts. Armitage JO." In Non Hodgkin Lymphomas.. 2nd ed. Edited by Armitage JO, Mauch PM., Harris NL., Coiffier B., Dalla-Favera R.. -. Philadelphia: Lippincott William and Wilkins, August 2010.
Porcu P, Wong HK. "Mycosis fungoides and Sezary Syndrome." In Treatment of Skin Disease, 4th Ed. 4th ed. Edited by Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I. -. Philadelphia: Elsevier, April 2013.
Alinari L, Porcu P, Coiffier B.. "Monoclonal antibodies (mAb) in the therapy of T-cell Lymphomas." In T-cell Lymphomas. -. New York: Humana Press, April 2013.
Porcu P, Wong HK. "Therapy of primary cutaneous lymphomas." In A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin.. Edited by Magro C.M., Crawson N.A., Mihrn M.C.. -. New Jersey:
Porcu P., Freud A. "Large Granular Lymphocyte Leukemia." In WILLIAMS HEMATOLOGY 9th Edition. Edited by Kaushansky, Lichtman, Prchal, Levi, Press, Burns, Caligiuri. -.
Gru A and Porcu P.. "Molecular Biology of T-cell Lymphomas." In Hematopathology of the Skin. Edited by Gru A, Schaffer A. - Walthers Kluwer Publisher. -.
Gru A, Porcu P.. "Molecular Biology of B-cell Lymphomas." In Hematopathology of the Skin. Edited by Gru A, Schaffer A - Walters Kluwer Publisher. -.
Wong HK, DaSilva S, Mishra A, Wu L, Porcu P.. "Epigenetics of Cutaneous T-cell Lymphoma." In Epigenetics and Dermatology. Edited by Lu, Chang, Robertson; Elsevier Publisher. -.
|01/01/2000||Outpatient Lymphoma Clinic (James Cancer Hospital)|
|01/01/2000||Annual In Patient Clinical Service (James Cancer Hospital, Hematology)|
|01/01/2000||Outpatient Multidisiplinary Clinic (James Cancer Hospital)|
Porcu P, Rougraff B, Shendrik I, Pietrafesa R, Parravicini C, Cattoretti G, Kotylo P, Orazi A. "MUM-1 and BCL-6 expression identifies distinct prognostic subgroups of primary diffuse large B-cell lymphoma (DLBCL) of the bone." In Blood. (November 2001). 334A-334A abstract #1411.
Link BK, Kahl B, Czuzman M., Powell BL, Bartlett N, Leonard JP, Ansell S, Porcu P, Byrd JC, Lazarus HM, Flinn I, Jones GJ, Levitt D, Hall WC, Weiner GJ. "A Phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma." In Blood. (November 2001). 606A abstract #2540-.
Copelan E, Avalos B, Pohlman B, Penza S, Kalacyo M, Sobecks R, farag S, Andresen S, Molina A., Kuczkowski E, Lin T, Marcucci G, Elder P. O’Donnel L, Porcu P, Mrozek E, Bolwell B.. "Delay of transplantation beyond first relapse of low-grade NHL adversely influences outcome.." In Blood. (November 2001). Abstract #2836-.
Porcu P, Farag S, Marcucci G, Avalos B, Rhoades C, Fisher B. Byrd JC, Grever MR, Caligiuri M... "Phase I trial of interleukin-2 (IL-2) and rituximab in patients (pts) with relapsed or refractory B-cell lymphomas (R/R-BCL).." In BLOOD. (November 2001). 245B-245B, abstract #4710.
Magro C, Crowson N, Porcu P, Nuovo JG. "Rapid diagnosis and molecular characterization of cutaneous B-cell lymphomas (CBCL) with a novel in-situ RT-PCR analysis of paraffin-embedded, formalin-fixed tissue.." In BLOOD. (November 2001). 129A-abstract #542.
Porcu P, Pelletier RP, Davis EA, Baiocchi RA., Eisenbeis CF, Roychowdhury S, Nuovo GJ, Marsh W, Vanbuskirk A, Henry ML, Ferguson RM, Caligiuri MA. "Post-transplant lymphoproliferative disorders following renal autografting: immunological and molecular monitoring identify correlates of clinical response to reduction of immunosuppression and antiviral therapy." In Cancer Research. (June 2001). 00-.
Lin TS, Flinn IW, LUCAS MS, Sickler J, Moran ME, Porcu P, Lucas DM, Grever MR, Byrd JC. "Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia: High frequency of cytomegalovirus disease and delayed neutropenia.." In BLOOD. (November 2002). 802A-803A.
Lin TS, Elder PJ, Penza SL, Avalos BR, Farag SS, Molina A, Mrozek E, Belt PS, Porcu P, Marcucci G, Byrd JC, Copelan EA. "Autologous stem cell transplants result in better 5-year overall, but not progression-free, survival than allogeneic transplants in patients with indolent non-Hodgkin's lymphoma.." In BLOOD. (November 2002). 644A-645A.
Eisenbeis CF, Leonard JW, Rosenblatt J, Khan K, Porcu P, Milan S, Wilson S, Hurst D, Caligiuri MA, Piro L.. "Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients.." In JOURNAL OF CLINICAL ONCOLOGY. (July 2004). 171S-171S.
Porcu P, Baiocchi RA, Buckner M, Byrd JC, Magro CM. "Bexarotene-induced T-cell immunomodulation and response in CTCL.." In BLOOD. (November 2004). 213A-213A.
TS Lin, B Fischer, ME Moran, MM Buckner, R Shank, EH Kraut, P Porcu, SS Farag, CF Eisenbeis, D Colevas, MR Grever, JC Byrd. "Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma." In BLOOD. (November 2005). 278A-278A abstract #994.
Francine Foss, Madeleine Duvic, Larisa Geskin, Joseph Anderson, Pierluigi Porcu, Raymond J. Hohl, Maureen Cooper, Jasmine M. Zain, John Zic, Patrica Hibberd, Mark Acosta. "Efficacy and safety of Denileukin diffitox (Ontak (R)) in the treatment of cutaneous T-cell lymphoma (CTCL) according to CD25 status.." In BLOOD. (November 2006). 766A-767A.
Porcu P, R Baiocchi, Lee J, Lin T, Blum K, Grady T, Grever M, Byrd JC. "Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: Preliminary results.." In JOURNAL OF CLINICAL ONCOLOGY. (June 2006). 445S-445S.
Blum KA, Lucas MS, Johnston JS, Dalton J, Young D, Baoicchi RA, Lin TS, Porcu P, Byrd JC. "Excessive neurotoxicity in a phase II trial of combined bortezomib and rituximab in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma.." In BLOOD. (November 2006). 784A-784A.
Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan,Sandra; Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis, CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. "A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma." In CLINICAL CANCER RESEARCH. (December 2006). 7046-7053.
Hamadani M, Awan F, Elder P, Lin T, Porcu P, Blum K, Benson D, Devine S. "Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma." In LEUKEMIA & LYMPHOMA. (January 2008). 1893-1898.
Gibson H, Wong H, Porcu P. "Epigenetic mechanisms regulate the T-Plastin (PLS3) gene, a gene highly expressed in Sezary T cells." In JOURNAL OF INVESTIGATIVE DERMATOLOGY. (April 2010). S30-S30 abstract #178.
Gibson H, Hake T, Porcu P, Wong H. "Proteasome inhibition with bortezomib suppresses T cell proliferation in a CTLA-4-dependent manner." In JOURNAL OF INVESTIGATIVE DERMATOLOGY. (April 2011). S102-S102 abstract #609.
Carlson SW, Magro CM, Porcu P, Wong HK. "Spontaneous resolution of a unilesional primary cutaneous CD8+CD30+lymphoproliferative disorder." In JOURNAL OF INVESTIGATIVE DERMATOLOGY. (April 2011). S14-S14 abstract #609.
Cohen JB, Hall N, Ruppert AS, Jones JA, Porcu P, Baiocchi RA, Penza S, Benson DM, Jr., Andritsos LA, Flynn JA, Devine SM, Blum KA. "The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma." In BLOOD. (November 2011). 1345-1346.
Christian B, Alinari L, Jones JA, Benson DM, Jr., Flynn JM, Porcu P, Lustberg ME, l Phelps M, Poi M, Chung D, Quinion C, Byrd JC, Wegener W, Goldenberg DM, Baiocchi RA, Blum KA. "Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma." In BLOOD. (November 2011). 1584-1584 abstract #3707.
Stephens DM, Ruppert AS, Christian B, Jones JA, Flynn JM, Porcu P, Baiocchi RA, Byrd JC, Dotson, EK, Crawford CS, Blum KA. "Toxicity in patients (pts) age 65 or older with dose-adjusted REPOCH (DA-REPOCH) for untreated diffuse large B-cell lymphoma (DLBCL).." In JOURNAL OF CLINICAL ONCOLOGY. (May 2012). abstract e18508-.
Kartono F, Wong HK, Porcu P. "Primary cutaneous B cell lymphomas: A review of clinicopathological presentation, characterization of prognostic markers, treatment, and outcome." In JOURNAL OF INVESTIGATIVE DERMATOLOGY. (May 2012). S97-S97 abstract #570.
Cohen JB, Ruppert AS, Heerema NA, Jones JA, Porcu P, Baiocchi RA, Christian B, Byrd JC, Flynn JM, Penza S, Andritsos LA, Devine SM, Blum KA. "Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL).." In BLOOD. (November 2012). abstract #2691-.
Chen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Jones JJ, Porcu P, Christian BA, Baiocchi RA, Maddocks K, Flynn J, Devine S, Blum KA. "Complete response (CR) to induction therapy in patients (pts) with myc+ and double hit non-Hodgkin’s lymphoma (NHL) is associated with prolonged progression-free survival (PFS)." In BLOOD. (November 2012). 2693-.
Kartono F, Elkins C., Frederickson J., Peter S., Wong HK., Porcu P. "Management and patterns of relapse for primary cutaneous B-cell lymphoma (PCBCL) at the Multimodality Cutaneous Lymphoma Clinic at the Ohio State University: a series update." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2012). S205-S206 abstract #9.
Salem G, Dunavin N, Wei L, Elder P, Penza S, Blum K, Porcu P, Baiocchi R, Jones J, Flynn J, Andritsos L, Devine SM, Christian B, Efebera Y. "Busulfan, cyclophosphamide, etoposide is not superior to carmustine, etoposide, cytarabine, mephalan conditioning prior to autologous stem cell transplantation in patients with Hodgkin's lymphoma and is associated with increased toxicity." In BONE MARROW TRANSPLANTATION. (April 2012). S84-S85.
Chan DV, Hake TS, Kartono F, Porcu P, Wong HK. "Identification of genes to reliably differentiate mycosis fungoides from psoriasis." In JOURNAL OF INVESTIGATIVE DERMATOLOGY. (May 2012). S99-S99 abstract #580.
Cohen JB, Geyer S, Lozanski G, Zhao W, Heerema NA, Jones JA, Porcu P, Christian B, Baiocchi RA, Maddocks K, Flynn JM, Devine SM, Blum, KA. "Complete Response (CR) to Induction Therapy in Patients (pts) with Myc plus and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS).." In BLOOD. (November 2012). abstract #2693-.
Hofmeister CC, Bowers MA, Baiocchi RA, Lozanski G, Humphries K, Blum KA, Porcu PA, Penza S, Greenfield CN, Sell M, Earl,Christian T, Zitesman J, Quinion C, Lustberg MA, Andritsos LA, Devine SM. "Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance." In BLOOD. (November 2012). abstract #2955-.
Cohen JB, Ruppert AS, Kaplan LD, Baiocchi R, Porcu P, Flynn J, Jones JA, Blum KA, Devine SM, Andritsos LA. "Complex Karyotype (CK) Is Associated with Increased Cumulative Incidence of Relapse (CIR) Following Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL) in First Remission." In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. (February 2012). suppl 2 pages S205-206, abst. #9.
Mishra A, Sullivan L, Sams G, Johns J, Curphey D, Falkenberg L, Gibson H, Liu S, Jaroncyk L, McConnell K, Wong H, La Perle K, Garzon R, Marcucci G, Porcu P, Caligiuri M. "Targeting HDAC1 in a novel model of cutaneous T-cell lymphoma." In Cancer Reasearch. (April 2013). abstract # 3857-.
Mishra A, La Perle K, Sullivan L, Sams GH, Curphey DP, McConnell K, Qi J, Wong HK, Kulp SK, Fernandez S, Bradner JE, Marcucci G, Ching-Shih Chen, Porcu P, Caligiuri MA. "Increased Expression Of IL-15 Promotes Cutaneous T-Cell Lymphomagenesis Via The Upregulation Of." In BLOOD. (October 2013). abstract #1826-.
Mishra A, Hake T, Gibson H, Sullivan L, Porcu P, Wong HK. "Aberrant non-lymphoid gene expression and promoter hypomethylation as biomarker for Sezary Syndrome." In JOURNAL OF INVESTIGATIVE DERMATOLOGY. (May 2013). S134-S134 abstract #791.
Chan, DV , Szabo, D, Frederickson J , Ziegler R, Kartono F, Porcu P, Wong, HK. "Romidepsin and PUVA therapy in refractory advanced stage CTCL is associated with remission and increased cell death and Fas expression." In JOURNAL OF INVESTIGATIVE DERMATOLOGY. (May 2013). S187-S187.
Flinn I, Patel M, Kahl B, Horwitz S, Foss FM, Oki Y, Porcu P, Sweeney J, Allen K, Faia K, Harris P, Dunbar J, Stern H, Kelly P, O’Brien S. "Preliminary Safety and Efficacy of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ in Patients with Chronic Lymphocytic Leukemia." In BLOOD. (October 2013). Abstract 677-.
Kim Y, Bagot M, Duvic M, Eradat H, Carson K, Greer J, Kim E, Kuzel T, Hughey L, Poligone B, Lansigan F, Zinzani P, Grandinetti L, Porcu P, Shustov A, Korman N, Halwani A, Kyowa Hakko Kirin Working Group Sokol L. "Phase 3 Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab versus Vorinostat in Subjects with Relapsed or Refractory Cutaneous T-cell Lymphoma (CTCL)." American Society for Clinical Oncology (ASCO). .
Horwitz S, Porcu P, Flinn I, Kahl B, Sweeney J, Stern H, Mark D, Allen K, Kelly P, Foss F. "Clinical Activity of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results from an Ongoing Phase I Study." 6TH TCell Lymphoma Forum. .
|1987||M.D., University of Torino Medical School|
|2002 - 2005||Leukemia – The Journal of Normal and Malignant Hematopoiesis|
|2004 - present||Journal of Clinical Oncology|
|2004 - present||European Journal of Hematology|
|2005 - present||Cancer Research|
|2006 - present||Clinical Cancer Research|
|2006 - present||Blood|
|2007 - present||Cancer|
|2008 - present||Leukemia|
|2010 - present||Frontiers in Hematology Oncology|
|2013 - present||Advances in Medicine|
|1999 - present||Merit Award. American Society of Clinical Oncology (ASCO).|
|2004 - present||Faculty Member Inductee of Alpha Omega Alpha. OSU Gamma Chapter.|
|2007 - present||ASCI/AAP Travel Award. ASCI/AAP Joint Meeting in Chicago.|
|2007 - present||Castle Connolly America’s Top Doctors for Cancer. Castle Connolly.|
|2009 - present||Nomination for Leonard Tow Humanism in Medicine Faculty Award. The Ohio State University.|
|2011 - 2013||Top 1% Cancer Doctors in the U.S.. US News World Report.|
|2014 - present||Certificate of Excellence. Faculty Group Practice.|
Pietrzkowski Z, Wernicke D, Porcu P, Jameson BA, Baserga R. "Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1." Cancer Research. Vol. 52, no. 23. (December 1992.): 6447-6451.
Porcu P, Ferber A, Pietrzkowski Z, Roberts CT, Adamo M, LeRoith D, Baserga R. "THE GROWTH-STIMULATORY EFFECT OF SIMIAN VIRUS-40 T-ANTIGEN REQUIRES THE INTERACTION OF INSULIN-LIKE GROWTH FACTOR-I WITH ITS RECEPTOR." Molecular and Cellular Biology. Vol. 12, no. 11. (November 1992.): 5069-5077.
Valentinis B, Porcu PL, Quinn K, Baserga R.. "The role of the insulin-like growth factor I receptor in the transformation by simian virus 40 T antigen." Oncogene. Vol. 9, no. 3. (March 1994.): 825-831.
Porcu P, Graña X, Li S, Swantek J, De Luca A, Giordano A, Baserga R.. "An E2f binding sequence negatively regulates the response of the insulin-like growth factor 1 (igf-i) promoter to simian virus 40 T antigen and to serum." Oncogene. Vol. 9, no. 8. (August 1994.): 2125-2134.
Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. "Therapeutic leukapheresis in hyperleucocytic leukaemias: Lack of correlation between degree of cytoreduction and early mortality rate." British Journal of Haematology. Vol. 98, no. 2. (August 1997.): 433-436.
Porcu P, Nichols CR. "Evaluation and management of the new lymphoma entities: Mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma." Current Problems in Cancer. Vol. 22, no. 5. (January 1998.): 279-368.
Porcu P, Gaddy J, Broxmeyer HE. "Alloantigen-induced unresponsiveness in cord blood T lymphocytes is associated with defective activation of Ras." Proceedings of the National Academy of Sciences of the United States of America. Vol. 95, no. 8. (April 1998.): 4538-4543.
McCarthy LJ, Porcu P, Fausel CA, Sweeney CJ, Danielson CF.. "Thrombotic thrombocytopenic purpura and simvastatin." LANCET. Vol. 352, no. 9136. (October 1998.): 1284-1285.
Ng EW, Porcu P, Loehrer PJ. "Sacrococcygeal teratoma in adults - Case reports and a review of the literature." Cancer. Vol. 86, no. 7. (October 1999.): 1198-1202.
Porcu P, Caligiuri MA. "Acquired immunodeficiency syndrome-related lymphomas: Future directions." Seminars in Oncology. Vol. 27, no. 4. (August 2000.): 454-462.
Porcu P, Bhatia S, Sharma M, Einhorn LH.. "Results of treatment after relapse from high-dose chemotherapy in germ cell tumors." Journal of Clinical Oncology. Vol. 18, no. 6. (January 2000.): 1181-1186.
Morrison C, Porcu P, Caligiuri MA, Nuovo GJ. "In situ determination of B-cell heavy chain and kappa/lambda light chain expression patterns: Methodology and clinical utility." Diagnostic Molecular Pathology. Vol. 10, no. 3. (September 2001.): 171-178.
Nuovo GJ, Morrison C, Porcu P, Caligiuri MA, Suster S. "In situ determination of T-cell receptor beta expression patterns." JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY. Vol. 49, no. 2. (February 2001.): 139-145.
Shah MH, Porcu P, Mallery SR, Caligiuri MA. "AIDS-associated malignancies.." Cancer chemotherapy and biological response modifiers. Vol. 20, (January 2002.): 633-664.
Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. "Leukocytoreduction for Acute Leukemia." THERAPEUTIC APHERESIS. Vol. 6, no. 1. (February 2002.): 15-23.
Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA. "Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration." Blood. Vol. 100, no. 7. (October 2002.): 2341-2348.
Porcu P, Baiocchi RA, MAGRO C. "Recent developments in the biology and therapy of T-cell and natural killer-cell lymphomas." Current Opinion in Oncology. Vol. 15, no. 5. (September 2003.): 353-362.
Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP. "Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia." Blood. Vol. 101, no. 2. (January 2003.): 425-432.
Magro C, Crowson AN, Porcu P, Nuovo GJ. "Automated kappa and lambda light chain mRNA expression for the assessment of B-cell clonality in cutaneous B-cell infiltrates: its utility and diagnostic application." Journal of Cutaneous Pathology. Vol. 30, no. 8. (September 2003.): 504-511.
Kiani B, Magro CM, Porcu P, Starns M, Heerema N, Ross P. "Polypoid endobronchial Hodgkin lymphoma with an initial response to photodynamic therapy." ANNALS OF THORACIC SURGERY. Vol. 76, no. 3. (September 2003.): 940-942.
Roychowdhury S, Baiocchi RA, Peng R, Bhatt D, Vourganti S, Grecula J., Gupta N., Eisenbeis CF, Nuovo GJ, Barth R, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Caligiuri MA. "Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma." Cancer Research. Vol. 63, no. 5. (March 2003.): 965-971.
Magro CM, Porcu P, Ahmad N, Klinger D, Crowson AN, Nuovo GJ. "Cutaneous immunocytoma: a clinical, histologic, and phenotypic study of 11 cases.." Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. Vol. 12, no. 3. (September 2004.): 216-224.
Eisenbeis CF, Granger A, Fischer B, Baiocchi RA, Carrodeguas L., Roychowdhury S., Chen L., Banks A., Davis T., Young D., Kelbick N., Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P. "Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study." CLINICAL CANCER RESEARCH. Vol. 10, no. 18. (September 2004.): 6101-6110.
Cosio M, Nuovo DL, Yearsley M, Porcu P, Caligiuri MC, Pelletier R, Nuovo GJ. "EBV kidney allograft infection: Possible relationship with a peri-graft localization of PTLD." AMERICAN JOURNAL OF TRANSPLANTATION. Vol. 4, no. 1. (January 2004.): 116-123.
Verma S, Nuovo GJ, Porcu P, Baiocchi RA, Crowson AN, Magro CM. "Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation." Journal of cutaneous pathology. Vol. 32, no. 1. (January 2005.): 35-39.
Verma S, Nuovo GJ, Porcu P, Baiocchi RA, Crowson AN, Magro CM. "Epstein-Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin." Journal of Cutaneous Pathology. Vol. 32, no. 7. (August 2005.): 474-483.
Lin TS, Flinn IW, Lucas MS, Porcu P, Sickler J, Moran ME, Lucas DM, Heerema NA, Grever MR, Byrd JC. "Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia." LEUKEMIA. Vol. 19, no. 7. (July 2005.): 1207-1210.
Vanbuskirk AM, Baiocchi RA, Ferketich A, Gross T, Porcu P, Caligiuri MA. "PTLD risk and IFNG polymorphisms - Response." BLOOD. Vol. 106, no. 4. (August 2005.): 1503-1503.
Rawal YB, Nuovo GJ, Franbach GE, Porcu P, Baiocchi RA, Magro CM. "The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy." JOURNAL OF CUTANEOUS PATHOLOGY. Vol. 32, no. 9. (October 2005.): 616-621.
Porcu, Pierluigi. "Profiling is a good thing (at least in the clinic).." Blood. Vol. 105, no. 5. (March 2005.): 1843-.
Porcu,Pierluigi. "New approaches to posttransplant lymphoproliferative disorder (PTLD).." Clinical advances in hematology & oncology : H&O. Vol. 3, no. 1. (January 2005.): 24-26.
Magro CM, Seilstad KH, Porcu P, Morrison CD. "Primary CD20+CD10+CD8+T-cell lymphoma of the skin with dual IgH and TCR beta gene rearrangement." AMERICAN JOURNAL OF CLINICAL PATHOLOGY. Vol. 126, no. 1. (July 2006.): 14-22.
Morrison C, Palatini J, Riggenbach J, Radmacher M, Porcu P.. "Fine-needle aspiration biopsy of non-hodgkin lymphoma for use in expression microarray analysis." CANCER CYTOPATHOLOGY. Vol. 108, no. 5. (October 2006.): 311-318.
Khan KD, Emmanouilides C, Benson DM Jr, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA. "A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.." Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 12, no. 23. (December 2006.): 7046-53.
Magro CM, Nash JW, Werling RW, Porcu P, Crowson N. "Primary cutaneous CD30+ large cell B-cell lymphoma - A series of 10 cases." APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY. Vol. 14, no. 1. (March 2006.): 7-11.
Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, Deng AC. "T-cell prolymphocytic leukemia: An aggressive T cell malignancy with frequent cutaneous tropism." Journal of the American Academy of Dermatology. Vol. 55, no. 3. (September 2006.): 467-477.
Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. "Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.." Journal of the National Comprehensive Cancer Network. Vol. 4, no. 3. (March 2006.): 258-310.
Breza TS Jr, Zheng P, Porcu P, Magro CM. "Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response." JOURNAL OF CUTANEOUS PATHOLOGY. Vol. 33, no. 7. (July 2006.): 522-528.
Magro CM, Nash JW, Werling RW, Porcu P, Crowson N. "CD8+lymphomatoid papulosis and its differential diagnosis." AMERICAN JOURNAL OF CLINICAL PATHOLOGY. Vol. 125, no. 4. (April 2006.): 490-501.
Opavski R, Tsai S, Guimond A, Opavska BM.,Kaufmann W, Stephens F, Muthusamy F, Porcu P, Caligiuri MA, Leone G. "Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis." Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 104, no. 39. (September 2007.): 15400-15405.
Blum W, Porcu P. "Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome." Seminars in thrombosis and hemostasis. Vol. 33, no. 4. (June 2007.): 350-354.
Magro CM, Weinerman DJ, Porcu P, Morrison CD.. "Post-transplant EBV-negative anaplastic large-cell lymphoma with dual rearrangement: a propos of two cases and review of the literature.." Journal of Cutaneous Pathology. Vol. 34, no. Suppl 1. (January 2007.): 1-8.
Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD. "Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901." LEUKEMIA & LYMPHOMA. Vol. 48, no. 1. (January 2007.): 97-103.
Hamadani M, Awan FT, Elder P., Lin TS, Porcu P, Blum KA., and Devine SM. "Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T-cell Lymphomas; Evidence of Graft-Versus-T-cell Lymphoma Effect." Biology of Blood & Marrow Transplantion. Vol. 14, no. 4. (April 2008.): 480-483.
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Klisovic RB, Baiocchi R, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G. "Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappa B-dependent DNA methyltransferase activity in acute myeloid leukemia." Blood. Vol. 111, no. 4. (February 2008.): 2364-2373.
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F; National Comprehensive Cancer Network.. "Non-Hodgkin's lymphomas.." J Natl Compr Canc Netw. Vol. 6, no. 4. (April 2008.): 356-421.
Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YM. "Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.." Journal of the National Comprehensive Cancer Network. Vol. 6, no. 4. (April 2008.): 436-442.
Hamadani,Mehdi; Awan,Farrukh,T; Elder,Patrick; Lin,Thomas,S; Porcu,Peirluigi; Blum,Kristie,A; Devine,Steven,M. "Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; Evidence of graft-versus-t cell lymphoma effect." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 14, no. 4. (April 2008.): 480-483.
Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM. "Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.." Leukemia & Lymphoma. Vol. 49, no. 10. (October 2008.): 1893-.
Hamadani M, Benson DM Jr., Lin TS, Porcu P, Blum KA, Devine SM. "High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma." European Journal Of Haematology. Vol. 81, no. 6. (December 2008.): 425-431.
Hamadani M, Magro CM, Porcu P.. "CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm).." British Journal Of Haematology. Vol. 140, no. 2. (January 2008.): 122-.
Alinari L., Geskin L, Grady T, Baiocchi RA, Bechtel MA, Porcu P. "Subcutaneous alemtuzumab for Sezary Syndrome in the very elderly." Leukemia Research. Vol. 32, no. 8. (August 2008.): 1299-1303.
Magro CM, Schaefer JT, Morrison C, Porcu P.. "Atypical lymphocytic lobular panniculitis: a clonal subcutaneous T-cell dyscrasia." Journal Of Cutaneous Pathology. Vol. 35, no. 10. (October 2008.): 947-954.
Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC. "Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma." Leukemia & Lymphoma. Vol. 50, no. 3. (January 2009.): 349-356.
Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM. "Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 15, no. 5. (May 2009.): 547-553.
Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA.. "Combination Bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma." MAbs. Vol. 1, no. 1. (January 2009.): 31-40.
Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC. "Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin’s lymphoma." Leukemia and Lymphoma. Vol. 50, no. 3. (March 2009.): 349-356.
Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC. "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia." Leukemia & Lymphoma. Vol. 50, no. 12. (January 2009.): 1958-1963.
Peruzzi PP, Ray-Chaudhury A, Slone WH, Mekhjian H, Porcu P, Chiocca EA. "Chemotherapy reverses neurologic deficit in Bcl-6 positive neurolymphomatosis." J. Neurosurgery. Vol. 111, no. 2. (August 2009.): 247-251.
Porcu P, Wong HK. "We should have a dream: unlocking the workings of the genome in cutaneous T-cell lymphomas.." Clinical Lymphoma & Myeloma. Vol. 9, no. 6. (December 2009.): 409-11.
Martin LK, Porcu P. Baiocchi RA., Erter JW, Chaudhury AR. "Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy.." Clinical advances in hematology & oncology : H&O. Vol. 7, no. 1. (January 2009.): 65-70.
Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran. "Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders." JOURNAL OF CLINICAL ONCOLOGY. Vol. 28, no. 3. (January 2010.): 418-423.
Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. "The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody." Blood. Vol. 116, no. 13. (September 2010.): 2286-2294.
Lessin SR, Porcu P. "The state of cutaneous lymphomas: a call to action.." Clinical Lymphoma, Myeloma & Leukemia. Vol. 10, no. S55. (September 2010.): Suppl. 2 pgs S55-58.
Tang N, Gibson H, Germeroth T, Porcu P, Lim HW, Wong HK. "T-plastin (PLS3) gene expression differentiates Sezary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression." BRITISH JOURNAL OF DERMATOLOGY. Vol. 162, no. 2. (February 2010.): 463-466.
Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel MA, Wong H, Porcu P.. "New Targets of Therapy in T-Cell Lymphomas." Current Drug Targets. Vol. 11, no. 4. (April 2010.): 482-493.
Magro CM, Porcu P Schaefer J, Erter JW, Furman RR, Shitabata PK, Crowson AN. "Cutaneous CD4(+) CD56(+) hematologic malignancies." Journal Of The American Academy Of Dermatology. Vol. 63, no. 2. (August 2010.): 292-308.
Porcu,Pierluigi. "A Look at the National Comprehensive Cancer Network Guidelines for Cutaneous Lymphomas." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. Vol. 10, (September 2010.): S109-S111.
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L,Vose JM, Wierda WG, Yahalom J, Yunus F. "NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas." J Natl Compr Canc Netw.. Vol. 8, no. 3. (March 2010.): 288-334.
Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA. "Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma." CANCER. Vol. 117, no. 11. (June 2011.): 2442-2451.
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. "Non-Hodgkin's Lymphomas." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Vol. 9, no. 5. (May 2011.): 484-560.
Mishra A, Porcu P. "Early CTCL diagnosis, a (miR)age no more?." BLOOD. Vol. 118, no. 22. (November 2011.): 5717-5718.
Porcu, P Caligiuri M. "A sheep in wolf's clothing.." Blood. Vol. 117, no. 5. (February 2011.): 1438-39.
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, DemierreM-F, Pittelkow M, Wilson LD, Pinter-Brown l, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. "Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)." Journal Of The American Academy Of Dermatology. Vol. 64, no. 2. (February 2011.): 352-404.
Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. "Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma." Leukemia & Lymphoma. Vol. 52, no. 8. (August 2011.): 1474-1480.
Wong HK, Mishra A, Hake T, Porcu P. "Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).." British Journal Of Haematology. Vol. 155, no. 2. (October 2011.): 150-166.
Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu LC, Hickey C, Chandler JC, Wu YZ, Heerema NA, Chan KK, Perrotti D, Zhang J, Porcu P, Racke FK, Garzon R, Lee RJ, Marcucci G, Caligiuri MA. "Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation." Cancer Cell. Vol. 22, no. 5. (November 2012.): 645-655.
Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED.. "A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype." Haematologica.. Vol. 97, no. 5. (May 2012.): 758-765.
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. "Non-Hodgkin's lymphomas.." Journal of the National Comprehensive Cancer Network : JNCCN. Vol. 6, no. 4. (December 2012.): 356-421.
Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. "Non-Hodgkin's lymphomas, version 1.2013.." J Natl Compr Canc Netw. Vol. 11, no. 3. (March 2013.): 257-273.
Kaffenberger BH, Kartono Winardi F, Frederickson J, Porcu P, Wong HK. "Periocular cutaneous anaplastic large cell lymphoma clearance with brentuximab vedotin." The Journal of clinical and aesthetic dermatology. Vol. 6, no. 8. (August 2013.): 29-31.
Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KA.. "Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma." BONE MARROW TRANSPLANTATION. Vol. 48, no. 9. (September 2013.): 1212-1217.
de Silva S, Hoy H, Hake TS, Wong HK, Porcu P, Wu L. "Promoter methylation regulates SAMHD1 gene expression in human CD4+ T cells." JOURNAL OF BIOLOGICAL CHEMISTRY. Vol. 288, no. 13. (March 2013.): 9284-9292.
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TS, Porcu P, Winter S. "US/Canadian intergroup randomized study (SWOG S9704) of autologous stem cell transplant for patients in first remission with diffuse aggressive non-Hodgkin's lymphoma in the high-intermediate or high International Prognostic Index risk groups." New England Journal of Medicine. Vol. 369, no. 18. (October 2013.): 1681-1690.
Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK. "Impaired Proteasome Function Activates GATA3 in T Cells and Upregulates CTLA-4: Relevance for Sézary Syndrome." J Invest Dermatol. Vol. 133, no. 1. (January 2013.): 249-257.
Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JC. "Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma." AMERICAN JOURNAL OF HEMATOLOGY. Vol. 89, no. 1. (January 2014.): 19-24.
Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, Christian BA, Baiocchi RA, Maddocks KJ, Flynn JM, Devine SM, Blum KA.. "Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.." Cancer. Vol. ., (February 2014.): .-.
de Silva S, Wang F, Hake TS, Porcu P, Wong HK, Wu L. "Downregulation of SAMHD1 Expression Correlates with Promoter DNA Methylation in Sezary Syndrome Patients." JOURNAL OF INVESTIGATIVE DERMATOLOGY. Vol. 134, no. 2. (February 2014.): 562-565.
Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA. "Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694." J Biol Chem. Vol. pii: jbc.M114.614891, (January 2015.): [Epub ahead of print]-.
Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.." Br J Haematol.. Vol. ., no. .. (April 2015.): .-.
Kaffenberger B, Haverkos B, Tyler K, Wong HK, Porcu P, Gru AA. "Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder." Am J Dermatopathol. Vol. ., no. .. (February 2015.): .-.
Kaffenberger B, Haverkos B, Tyler K, Wong HK, Porcu P, Gru A. "Extranodal marginal zone lymphoma (MALT)-like presentation of angioimmunoblastic T-cell lymphoma: A T-cell lymphoma masquerading as a B-cell lymphoproliferative disorder.." American Journal of Dermatopathology. -.
|December 2012||Patti, Michael."Helped developing and launching the USCLC website" Sherwood, Inc. Deerwood IL|
"Alloantigen-induced unresponsiveness in cord blood T-lymphocytes is associated with defective activation of Ra." Presented at ASH 39th Annual Meeting, San Diego, CA. (December 1997)
"AIDS and other Immunodeficiencies: Basic, Epidemiologic, and Clinical Research." Presented at Sixth International Conference on Malignancies in AIDS and other Immunodeficiencies, Washington, DC. (April 2002)
"Treatment of Lymphoma with IL-2 and Rituximab." Presented at Sixth Annual Meeting of the Regional Cancer Center Consortium for the Biological Therapy of Cancer, Columbus, OH. (February 2002)
"Co Chair: Proleukin International Clinical Development Conference." Presented at Lugano Lymphoma Meeting, Milano, IT|ITA. (June 2002)
"“Therapy of Leukemia by Design”." Presented at ASH 44th Annual Meeting Scientific Symposium, Philadelphia, PA. (December 2002)
"The use of monoclonal antibodies in the treatment of B-cell lymphoma." Presented at Charleston Area Oncology Group Tumor Board, Charleston, WVA. (January 2002)
"Update on the Management of CLL." Presented at Tumor Board, Norwich, CT. (December 2003)
"Bexarotene-induced immunomodulation and response in CTCL." Presented at ASH 46th Annual Meeting, San Diego, CA. (December 2004)
"Emerging Cancer Treatment Modalities." Presented at Moffitt Cancer Center merging Cancer Treatment Modalities, Copper Mountain, CO. (March 2004)
"Update on the biology and therapy of T-cell lymphomas." Presented at Cancer Center Grand Rounds, New York, NY. (June 2004)
"Biology and therapy of T-cell lymphoma." Presented at Our Lady of Mercy Medical Center Cancer Ground Rounds, New York, NY. (September 2004)
"New targets for treatment of lymphoproliferative disorders." Presented at Spanish Society of Haematology and Haematotherapy (AEHH), 46th Annual Meeting, Valencia, ES|ESP. (October 2004)
"Immunotherapy of Lymphoma." Presented at Washington Hospital Center/Washington Cancer Institute, Washington, DC. (January 2004)
"Hematological Malignancies." Presented at Whistler Winter Conference on Hematological Malignancies, Whistler, CA|CAN. (February 2005)
"The use of monoclonal antibodies in the treatment of lymphoma." Presented at Charleston Area Oncology Group Tumor Board, Charleston, WVA. (January 2005)
"Cutaneous T-cell Lymphomas." Presented at Cutaneous T-cell Lymphomas Master Conference, Dallas, Texas. (March 2005)
"Campath-1H (Phase III clinical trial in T-cell lymphoma)." Presented at Campath-1H Investigatorâ€™s Meeting, ATLANTA, GEORGIA. (December 2005)
"Optimizing Targeted Therapies, Chemotherapy and Immunotherapy including CHOP and Denileukin Diftitox." Presented at CTCL Regional Masters Conference, Pittsburgh, PA, US|USA. (October 2006)
"Research in Review: Viral Oncogenesis Program." Presented at OSUCCC Viral Oncogenesis Program Retreat, Columbus, OH. (March 2006)
"Cancer Care Across the Continium: New, Discoveries, New Modalities." Presented at Cancer Care Across the Continium: New, Discoveries, New Modalities Conference, Columbus, OH. (March 2006)
"Life and Times of Rituximab: Good Things From Bad Diseases." Presented at Symposium on Susacâ€™s Syndrome 2006 An Autoimmune Microvascular Endtoheliopathy, Columbus, Ohio. (April 2006)
"Alemtuzumab and allogeneic BMT in the treatment of Sezary Syndrome." Presented at 67th Annual Meeting of the Society of Investigative Dermatology (SID), Working Group on Sezary Syndrome, . (May 2006)
"“T-cell disorders”." Presented at Exciting new Developments in Hematology – American Society of Hematology (ASH) review, Columbus, Ohio. (May 2006)
"B-Cell Malignancies Education Network." Presented at B-Cell Malignancies Education Network, Lima, OH. (June 2006)
"PTCL: Innovative Treatments MS-275." Presented at It’s time to take care of T-Cell Lymphomas Conference, Bologna, IT|ITA. (October 2006)
"International Society of Cutaneous Lymphomas (ISCL) Workshop, Evidence-based review of current therapeutic agents in Sezary Syndrome (US Initiative): Campath." Presented at International Society of Cutaneous Lymphomas (ISCL), Washington, US|USA. (February 2007)
"Biology and therapy of cutaneous T-cell lymphoma." Presented at Central Ohio Dermatology Society Meeting, Columbus, OH, US|USA. (April 2007)
"A vaccine-based strategy to enhance Epstein Barr Virus (EBV)-specific T-cell responses to prevent post-transplant lymphoproliferative disorder (PTLD)." Presented at American Society of Clinical Investigation/Association of American Physicians Joint Meeting, Chicago, IL, US|USA. (April 2007)
"Review and interpretation of the ASCO, ASH and AACR meetings.." Presented at Oncology & Hematology 2007, Columbus, OH, US|USA. (June 2007)
"Post Transplant Lymphoproliferative Disease (PLTD)." Presented at OSU College of Pharmacy Lecture Series, Columbus, OH, US|USA. (November 2007)
"International Society of Cutaneous Lymphomas (ISCL)." Presented at Meeting of the North American Group, San Antonio, TX, US|USA. (January 2008)
"Discussion of CTCL cases." Presented at Lymphoma Tumor Board, Pittsburgh, PA, US|USA. (May 2008)
"Alemtuzumab (anti-CD52)." Presented at Peripheral T-cell Lymphoma Forum, Washington, US|USA. (September 2008)
"New Therapies in T-cell Lymphoma.." Presented at T-cell Lymphoma, Bologna, IT|ITA. (October 2008)
"Cutaneous Lymphomas." Presented at Cutaneous Lymphoma Summit, . (October 2009)
"Scientific Program /Patient Forum." Presented at Cutaneous Lymphoma Summit, New York City, NY, US|USA. (October 2009)
"Now we know T-cell lymphoma better." Presented at Istituto L. and A. Seragnoli, University of Bologna, IT|ITA. (March 2009)
"American Cancer Society." Presented at State of Ohio Congressional Research Briefing, Columbus, OH, US|USA. (May 2010)
"Systemic Treatment Overview and open discussion with patients." Presented at Cutaneous Lymphoma Foundation Patient Educational Forum, Denver, CO. (May 2011)
"T-Cell Lymphoma from Genes to Therapy." Presented at Hematology/ Oncology 5th Annual Symposium: Science and Practice of Cancer Management, Savannah. (September 2011)
"Cutaneous Lymphoma Foundation Patient Educational Forum." Presented at Cutaneous Lymphoma Foundation Patient Educational Forum, Columbus, OH. (May 2012)
"Emerging Treatment Options in Cutaneous T-cell Lymphoma." Presented at World Cutaneous Malignancies Congress 2013, San Diego, CA. (July 2013)
"Management of PTCL." Presented at 17th International Congress on Hematologic Malignancies, New York, NY, US|USA. (February 2013)
"Oral Session in the Scientific Program: Non-Hodgkin’s Lymphoma: Biology, excluding Therapy: Molecular Pathogenesis." Presented at 55th Annual American Society for Hematology Conference, . (December 2013)
"The Approach to the Patient with Cutaneous T-Cell Lymphoma." Presented at 72nd Annual Meeting for the American Academy for Dermatology, Denver, CO, US|USA. (March 2014)
"Cutaneous Lymphoma." Presented at 2014 Lymphoma Workshop, Chicago, IL. (May 2014)
"The role of HDACi in CTCL." Presented at T-cell Lymphoma Forum, . (January 2014)
|present||Frankly speaking about lymphoma. Cure for Lymphoma Foundation (CLF).|
|present||Meeting of the Western Ohio, Eastern Indiana, and Kentucky (WOEINKY) WM Support Group.. International Waldenstrom Macroglobulinemia Foundation (IWMF).|
|present||Meet the Expert on Non-Hodgkin's. The Leukemia and Lymphoma Society (LLS). Lima, Ohio.|
|present||Meet the Expert on Lymphoma: New Insights and Treatments. The Leukemia and Lymphoma Society (LLS). Lima, Ohio.|
|present||Central Ohio Blood Cancer Conference. The Leukemia and Lymphoma Society (LLS). Columbus, Ohio.|
|present||“Ask the Doctor about WM” 1st regional meeting WM Support Group. International Waldenstrom Macroglobulinemia Foundation (IWMF). Troy, Ohio.|
|present||Skills for communicating with your health care provider. Leukemia Society of America (LSA) Central Ohio Chapter.|
|present||National teleconference on Lymphoma Update. Cure for Lymphoma Foundation (CLF).|
|present||Opening Remarks to Relay for Life® participants. American Cancer Society (ACS). Piketon, Ohio.|
|present||Strategic Plan for Non Profit Organization. United States Cutaneous Lymphoma Consortium (USCLC).|
|present||Grant Reviewer. Netherlands Organization for Scientific Research (NWO) (CTCL).|
|present||Ohio Delegation, Lymphoma, Leukemia and Myeloma Advocacy Day and Congressional Hearing.. Cure for Lymphoma Foundation (CLF).|
|2000 - present||Grant Reviewer. V Foundation proposals.|
|2003 - present||Ligand Consultant Advisory Meeting. Chicago, IL.|
|2005 - present||Genzyme CTCL Expert Panel. Genzyme. Cambridge, MA.|
|2006 - present||Ligand Pharmaceuticals, CTCL Expert Panel. Ligand Pharmaceuticals. Chicago, IL.|
|2006 - present||Cutaneous Lymphoma Patient Forum. Cutaneous Lymphoma Foundation (CLF).|
|2007 - present||Merck CTCL Expert Panel. Merck. Chicago, IL.|
|2007 - present||Shook, Hardy & Bacon, LLP (Houston): External consultant on drug-related T-cell lymphomas. Shook, Hardy & Bacon, LLP. Houston, TX.|
|2007 - present||BioStrategies Consulting Group: Expert consultant on new drugs in PTCL. BioStrategies Consulting Group.|
|2007 - present||Chair, CTCL Expert Panel and Advisory Board, Eisai Pharmaceuticals. Eisai Pharmaceuticlas. Columbus, OH.|
|2008 - present||Merck CTCL US Clinical Advisory Board.|
|2010 - present||Allos Therapeutics, Inc. Pralatrexate Advisory Board Meeting. Allos Therapeutics, Inc.. Orlando, FL.|
|2011 - present||Oncology National Advisory Board Meeting. AMGEN Oncology.|
|2011 - present||Celgene PTCL Steering Committee. Celgene Corporation. Alexandria, VA.|
|2011 - present||Cutaneous Lymphoma Advisory Board Meeting. Cutaneous Lymphoma Foundation.|
|2011 - present||NCCN Non-Hodgkin's Lymphomas Panel Meeting. National Comprehensive Cancer Network.|
|2012 - present||Medicis Clinical Consultancy Meeting-CTCL. Medicis Pharmaceutical Corp.. Scottsdale, AZ.|
|2012 - present||Cutaneous Lymphoma Advisory Board Meeting. Cutaneous Lymphoma Foundation.|
|2000||Speaker: National teleconference on Lymphoma Update. Cure for Lymphoma Foundation (CLF).|
|2000||Speaker: Central Ohio Chapter: Skills for communicating with your health care provider. Leukemia Society of America (LSA).|
|2000 - 2001||Speaker: The Wellness Community, Columbus, OH. “Ask the doctor about lymphoma”.. Lymphoma Research Foundation of America (LRFA).|
|- 2009||Speaking Series: Meet the Doctor. The Leukemia and Lymphoma Society (LLS).|
|2007 - 2011||Open telephone discussion with disease specific patients. Cancercare®.|
|2011||Grant Reviewer. National Medical Research Council, Singapore (T-cell lymphoma).|
Mishra A, Gibson H., Hake T., Geyer S., Frederickson J., Marcucci G., Caligiuri MA., Porcu P.,. Genome wide and promoter-specific hypomethylation is associated with overexpression of Twist1, GATA6, and T-plastin in Sezary Syndrome. May 2014.
Kaffenberger B, Haverkos B, Tyler K, Wong H, Porcu P, Gru AA,. Extranodal Marginal Zone Lymphoma (MALT) – Like Presentations of Angioimmunoblastic T-cell lymphoma: A T-cell lymphoma masquerading as a B-cell lymphoproliferative disorder.. July 2014.
Tyler K, Haverkos B, Gru A, Wong HK, Porcu P. multidisciplinary clinic model for care, discovery, and education in cutaneous lymphoma. August 2014.
Hofmeister CC, Williams N, Geyer S, Hade E, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphrie K, Lozanski G, Baiocchi R, Jaglowski S, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos L, Devine S. A Phase 1 study of Vorinostat Maintenance after Autologous Transplant in High Risk Lymphoma. August 2014.